Karl Wallendszus
BSc, MSc
Senior Analyst/Programmer
Karl Wallendszus works on the analysis of a number of clinical trials in the Heart Studies Group of the Clinical Trial Service Unit (CTSU). This involves developing, with others in the data analysis team, a system to prepare data using CDISC standards and analyse it in a way which is standardised and traceable, and produce output suitable for publications, clinical study reports, regulatory submissions and data sharing. Karl has used this system, which is constantly evolving in response to technological innovations and regulatory requirements, in the analysis of studies such as HPS, SEARCH, THRIVE, SHARP, REVEAL, ASCEND, LENS, ORION-4 and EMPA-KIDNEY. He has presented aspects of this work to other groups within the University as well as at international clinical trial methodology and data standards conferences.
Karl graduated in Zoology from St Peter’s College, Oxford in 1984 and went on to gain an MSc in Biological Computation at York University. He then worked for the UK Children’s Cancer Study Group in Manchester and Leicester, before returning to Oxford in 1989 to join CTSU. There he developed various applications used in the running of clinical trials, before specialising in data analysis for the main study results of HPS, which were published in 2002.
Recent publications
-
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
Journal article
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications
-
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Journal article
Harper C. et al, (2023), Heart
-
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
-
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials